Results 231 to 240 of about 111,189 (247)

‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’

Oncogene, 2007
Benjamin Bonavida, Bonavida B
exaly  

Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Autoimmunity Reviews, 2013
Ricard Cervera, Ignasi Rodríguez-Pinto, Doruk Erkan   +2 more
exaly  

A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function

American Journal of Transplantation, 2013
Luuk Hilbrands, Elena Kamburova, Irma Joosten   +2 more
exaly  

Rituximab

Reactions Weekly, 2023
openaire   +1 more source

Pharmacokinetics of rituximab and its clinical use: Thought for the best use?

Critical Reviews in Oncology/Hematology, 2007
Hervé Watier, Gilles Paintaud, Guillaume Cartron   +2 more
exaly  

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

Diabetes Care, 2014
Desmond Schatz, Antoinette Moran, Jay Skyler   +2 more
exaly  

Rituximab

Reactions Weekly, 2012
openaire   +1 more source

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Annals of Oncology, 2011
Mushui Dai, Andrew Evens, T -Y Chen
exaly  

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody‐mediated disease

British Journal of Clinical Pharmacology, 2013
Melanie White-Koning, Florent Puisset, Pr Lionel Rostaing   +2 more
exaly  

Rituximab

Reactions Weekly, 2008
openaire   +1 more source